HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Shiro Mawatari Selected Research

Plasmalogens

1/2022Orally Administered Plasmalogens Alleviate Negative Mood States and Enhance Mental Concentration: A Randomized, Double-Blind, Placebo-Controlled Trial.
1/2020Identification of plasmalogens in Bifidobacterium longum, but not in Bifidobacterium animalis.
1/2020Improvement of Blood Plasmalogens and Clinical Symptoms in Parkinson's Disease by Oral Administration of Ether Phospholipids: A Preliminary Report.
1/2020Therapeutic Efficacy of Plasmalogens for Alzheimer's Disease, Mild Cognitive Impairment, and Parkinson's Disease in Conjunction with a New Hypothesis for the Etiology of Alzheimer's Disease.
3/2018Enzymatic measurement of ether phospholipids in human plasma after hydrolysis of plasma with phospholipase A1.
3/2017Efficacy and Blood Plasmalogen Changes by Oral Administration of Plasmalogen in Patients with Mild Alzheimer's Disease and Mild Cognitive Impairment: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial.
8/2012Anti-inflammatory/anti-amyloidogenic effects of plasmalogens in lipopolysaccharide-induced neuroinflammation in adult mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Shiro Mawatari Research Topics

Disease

4Alzheimer Disease (Alzheimer's Disease)
01/2020 - 01/2012
3Neuroinflammatory Diseases
01/2020 - 07/2012
3Parkinson Disease (Parkinson's Disease)
01/2020 - 03/2018
2Cognitive Dysfunction
01/2020 - 03/2017
1Fatigue
01/2022
1Sleep Initiation and Maintenance Disorders (Insomnia)
01/2022
1Hemolysis
01/2022
1Sickle Cell Anemia (Hemoglobin S Disease)
01/2022
1Dementia (Dementias)
01/2020
1Neurodegenerative Diseases (Neurodegenerative Disease)
01/2020
1Schizophrenia (Dementia Praecox)
03/2018
1Metabolic Syndrome (Dysmetabolic Syndrome X)
03/2018
1Body Weight (Weight, Body)
11/2012
1Insulin Resistance
06/2010
1Hypercholesterolemia
06/2010
1Fatty Liver
06/2010
1Carcinogenesis
06/2010

Drug/Important Bio-Agent (IBA)

7PlasmalogensIBA
01/2022 - 08/2012
2Phospholipids (Phosphatides)FDA LinkGeneric
01/2022 - 01/2012
2Phospholipid EthersIBA
01/2020 - 03/2018
2LipopolysaccharidesIBA
08/2012 - 07/2012
1NickelIBA
01/2022
1MethemoglobinIBA
01/2022
1Sickle HemoglobinIBA
01/2022
1Membrane Proteins (Integral Membrane Proteins)IBA
01/2022
1Biological ProductsIBA
01/2020
1Sulfalene (Longum)IBA
01/2020
1AlbuminsIBA
11/2012
1Glucose (Dextrose)FDA LinkGeneric
11/2012
1Triglycerides (Triacylglycerol)IBA
11/2012
1Glycerophospholipids (Phosphoglycerides)IBA
08/2012
1phosphatidal ethanolaminesIBA
01/2012
1SphingolipidsIBA
06/2010
1LipidsIBA
06/2010
1AdiponectinIBA
06/2010
1CholesterolIBA
06/2010

Therapy/Procedure

2Oral Administration
01/2020 - 03/2017
1Therapeutics
01/2020